News
CDTX
0.5528
+7.57%
0.0389
Cantor Fitzgerald Reiterates Overweight on Cidara Therapeutics
Benzinga · 1h ago
Why Hibbett Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
Shares of Hibbett, Inc. Rose sharply in today's pre-market trading. The company agreed to be acquired by JD Sports Fashion for $87.50 per share in cash. Pineapple Energy Inc. Shares gained 38% to $0.0632 after falling 10% on Monday. ImmunityBio, Inc., AGBA Group Holding Limited and HWH International were among the stocks moving in pre- market trading.
Benzinga · 2h ago
CIDARA THERAPEUTICS SHARES UP 11.9% PREMARKET AFTER HIGHER Q4 REV, NARROWER LOSS
Reuters · 4h ago
CDTX Stock Earnings: Cidara Therapeutics Beats EPS, Beats Revenue for Q4 2023
Cidara Therapeutics reported earnings per share of -4 cents for the fourth quarter of 2023. The company reported revenue of $17.58 million. This was 52.37% better than the analyst estimate for revenue in the same period. CidaraTherapeutics also reported results for the third quarter.
Investorplace · 12h ago
Financial Report: Cidara Therapeutics, Inc. - Form 10-K for the fiscal year ended December 31, 2023
Press release · 14h ago
Cidara Theraptcs: Annual report
Press release · 14h ago
Cidara Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Cidara Therapeutics Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of 4 cents per share. Revenue rose 72.1% to $17.58 million from a year ago. Cidara shares have fallen by 26.0% this quarter and 14.2% this year.
Reuters · 16h ago
Cidara Therapeutics Q4 EPS $(0.04) Beats $(0.10) Estimate, Sales $14.72M Beat $11.54M Estimate
Cidara Therapeutics reported quarterly sales of $14.72 million. The company beat the analyst consensus estimate of $11.54 million by 27.52%. The company reported quarterly losses of $0.04 per share. Cidara reported a 78.95 percent increase over the same period last year.
Benzinga · 17h ago
CIDARA THERAPEUTICS PROVIDES CORPORATE UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS
Reuters · 17h ago
*Cidara Therapeutics 4Q Loss $3.21M >CDTX
Dow Jones · 17h ago
Press Release: Cidara Therapeutics Provides -2-
This release contains "forward-looking statements" that are subject to a multitude of risks and uncertainties. Cidara's future results could differ from those projected in the forward-looking statement. The company is a leader in the development of DFCs and is developing a new line of drugs for influenza.
Dow Jones · 17h ago
*Cidara Therapeutics 4Q Rev $17.6M >CDTX
Dow Jones · 17h ago
*Cidara Therapeutics 4Q Loss/Shr 4c >CDTX
Dow Jones · 17h ago
CIDARA THERAPEUTICS ANNOUNCES RECEIPT OF NASDAQ DELINQUENCY NOTICE
Reuters · 17h ago
Why Cidara Therapeutics (CDTX) Stock Is Falling
Cidara Therapeutics Inc shares are trading lower by 24.4% to $0.52 Monday afternoon. The company announced a 1-for-20 reverse stock split. Each 20 shares of existing common stock will be combined into one share. The reverse split follows approval from stockholders on April 4.
Benzinga · 18h ago
Cidara Therapeutics to implement a reverse stock split
Cidara Therapeutics to implement a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-20. The company's common stock will begin trading on a split-adjusted basis on April 24. CidaraTherapeutics, Inc. (CDTX) Stock.
Seeking Alpha · 1d ago
Cidara Therapeutics Announces 1-For-20 Reverse Stock Split, Will Begin Trading On A Split-Adjusted Basis Commencing Upon Market Open On April 24, 2024
Cidara Therapeutics, Inc. Effected a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-20. The Company's common stock will begin trading on a split-adjusted basis on April 24, 2024. Each 20 shares of the Company's stock will be automatically combined and converted into one share of common stock.
Benzinga · 1d ago
*Cidara Therapeutics Announces 1-for-20 Reverse Stock Split
Dow Jones · 1d ago
CIDARA THERAPEUTICS INC: COMMON STOCK WILL BEGIN TRADING ON A SPLIT-ADJUSTED BASIS COMMENCING UPON MARKET OPEN ON APRIL 24
Reuters · 1d ago
More
Webull provides a variety of real-time CDTX stock news. You can receive the latest news about Cidara Theraptcs through multiple platforms. This information may help you make smarter investment decisions.
About CDTX
Cidara Therapeutics, Inc. is a biotechnology company. The Company is focused on the discovery, development and commercialization of therapeutics designed for patients facing serious diseases. The Company's lead product candidate is rezafungin acetate, an intravenous formulation of an echinocandin. Rezafungin is being developed as a once-weekly, high-exposure therapy for the treatment and prevention of serious invasive fungal infections. The Company’s primary focus is using its Cloudbreak platform to develop a potential new class of drugs called drug-Fc conjugates (DFCs), for the prevention and treatment of serious diseases. This technology couples’ potent inhibitors to a human antibody fragment to create long-acting DFCs designed to inhibit multiple disease targets. Its advanced DFC program is CD388, a long-acting antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase I and Phase IIa clinical trials.